Curt I. Civin, Md
Professor
Pediatrics
University of Maryland Medical Center
United States of America
Biography
Dr. Civin is a pioneer in cancer research who is known internationally for developing a way to isolate stem cells from other blood cells The founding director for the University of Maryland’s Center for Stem Cell Biology & Regenerative Medicine, he has received wide recognition for his groundbreaking 1984 discovery of the CD34 antibody, which has had a major impact on the field of blood research. . Through his laboratory work, Dr. Civin accomplished the rare feat of making multiple discoveries that are used today not only in laboratory research but also in clinical bone marrow stem cell transplantation and leukemia diagnosis. Dr. Civin holds 12 biomedical patents and is currently a principal or collaborating investigator on 11 peer-reviewed research projects funded by the National Institutes of Health, the state of Maryland Stem Cell Research Fund, the Leukemia & Lymphoma Society, the National Foundation for Cancer Research, and other private foundations. Dr. Civin taught and led research and clinical pediatric oncology at Johns Hopkins University School of Medicine for 30 years before becoming founding director for the University of Maryland’s Center for Stem Cell Biology & Regenerative Medicine and Associate Dean for Research. He has lectured around the world, published more than 250 articles and book chapters, received many awards, and served in leadership positions of multiple distinguished committees and editorial boards. Throughout his career, he has mentored a large number of talented scientists to pursue academic careers in translational research.
Research Interest
Stem Cell Biology, Regenerative Medicine, Pediatrics, Physiology, Pediatric Oncology, Gene Therapy, Pediatric Hematology, Childhood Cancer, Childhood Leukemia, Pediatric Bone Marrow Transplantation, Myeloid Diseases
Publications
-
Huang T.C., Cutler J., Bharne S., Zhong J., Weinstock D., Tyner J., Gojo I., Civin C.I., Pandey A. Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-Like Kinase 1 as a potential therapeutic target. Leuk Lymphoma In Press, 2014. PMID: 25213184
-
Farrance, I.K., Civin, C.I. (eds.) Special Issue: Biochemistry of Stem Cells. In Biochimica et Biophysica Acta 1830, 2013.
-
Tan Y.S., Kim M.J., Kingsbury T.J., Civin C.I., Cheng W.C. Regulation of RAB5C is important for the growth inhibitory effects of miR-509 in human precursor-B acute lymphoblastic leukemia. PLoS One 9:e111777, 2014. PMID: 25368993 PMCID: PMC4219775